Introduction
Photodynamic therapy (PDT) is a treatment modality in which a photosensitizer (PS), light, and oxygen are used to produce reactive oxygen species (ROS). ROS can cause damage to different cell organelles which ultimately leads to cell death. Furthermore, the intrinsic fluorescence of PSs can be used for photodetection (PD).
5-aminolevulinic acid (5-ALA) is a natural precursor of heme in heme biosynthesis that takes part partially in mitochondria and partially in the cytosol in nearly all cells containing a nucleus ( Figure 1) . In malignant cells, the exogenous administration of 5-ALA causes the temporary accumulation of a natural PS protoporphyrin IX (PpIX) due to the bypass of the feedback control mechanism governed by the free heme. This can be ascribed to altered activities of the enzymes involved in heme biosynthesis. [1] [2] [3] The endogenously produced PpIX is nowadays efficiently exploited in 5-ALA-mediated PDT and PD. 5-ALA PDT demonstrates many advantages over PDT performed with conventional PS. Since 5-ALA does not possess properties of a PS, its administration does not provoke major photosensitivity reactions caused by PS accumulation in non-targeted tissues hence providing the possibility of repeated administration with reduced side effects. Moreover, PpIX produced after the administration of 5-ALA may be used not only for PDT, but also for diagnostic purposes to identify the early changes in tissues by means of fluorescence PD. During surgery, PD allows the identification and resection of very small lesions which are usually missed by conventional nakedeye examination. 4 Although primary employed in the treatment of dermatological conditions like actinic keratosis (AK), psoriasis, basal cell carcinoma, squamous cell carcinoma and Bowen's disease, 5-ALA has been tested for the treatment or detection of different malignancies ranging from brain tumors to lung cancer. 5, 6 Today, 5-ALA has been granted marketing authorization for the treatment of AK [7] [8] [9] [10] and the fluorescence-guided resection of malignant glioma. 4, 11, 12 Although showing promise for PDT and PD, 5-ALA has certain drawbacks when it comes to its physicochemical properties. Being a charged zwitterion under physiological conditions, 5-ALA cannot efficiently pass biological barriers. Its limited bioavailability and poor pharmacokinetic profile make 5-ALA suboptimal for systemic administration. 13 To overcome these shortcomings, different strategies have been employed. Up to now, making the molecule more lipophilic by esterification of its carboxyl function has provided the most effective solution reducing the dose needed for the optimal PpIX production up to 150-fold.
14 Nowadays, 5-ALA-methyl ester (Metvix®) 15 is granted use for the treatment of AK and basal cell carcinoma and 5-ALA-hexyl ester (ALA-Hex, Hexvix®) for the detection of bladder cancer. [16] [17] [18] [19] Albeit improved in the terms of lipophilicity, ALA-Hex remains toxic with a poor systemic pharmacokinetic profile thus still not providing an optimal solution for the systemic administration. 20 In order to circumvent the problem of poor drug-like properties of 5-ALA and its esters, we recently reported new 5-ALA prodrugs where the amino group of ALA-Hex was modified with a phosphatase-sensitive linker. 21 The presence of phosphatase activity in various tissues and their upregulated expression in certain types of cancer might provide a solution for a broader clinical application of 5-ALA PDT and PD. [22] [23] [24] [25] Phospho-self-immolative 5-ALA (PSI-ALA-Hex) and phospho-5-ALA (P-ALA-Hex) keep the lipophilicity of ALA-Hex which facilitates their uptake into cells compared to 5-ALA while having reduced acute toxicity and improved stability over a wide range of pH values. In addition, their activation and conversion to 5-ALA is controlled and can be tailored with changes to chemical structure ( Figure 2 ).
In this work we present comprehensive in vitro evaluation of phosphatase-sensitive prodrugs of 
Materials and methods

Chemistry
The compounds PSI-ALA-Hex, P-ALA-Hex and ALA-Hex were synthesized according to published procedure. 21 The compounds were stored at -25 °C and dissolved in cell media before the experiments.
PSI-ALA 
PpIX fluorescence measurements
Cells were plated in different densities according to their growth rate. T24 (5000 cells/well), calculated and plotted for each cell. All figures were generated using GraphPad Prism 6 software. P-value < 0.05 was considered as statistically significant.
Comparison of PpIX production in cells by flow cytometry
Cells (PC3, MCF7, T24 and A549) were seeded in 6 well plates (flat bottom cell and -1 (perfect negative correlation), where 0 means no correlation 26 . PCC was calculated in defined regions of interest (ROI). ROI was defined for each image separately by masking the dataset with red channel (PpIX fluorescence). The value of PCC for each experiment is presented as means ± s.d. calculated from 3 separate images.
Results
Influence of different 5-ALA derivatives on PpIX production
Time-dependent PpIX production was evaluated over 24 h in PC3 human prostate cancer, MCF7 breast adenocarcinoma, U87MG glioblastoma, T24 bladder carcinoma and A549 lung adenocarcinoma cells exposed to PSI-ALA-Hex, P-ALA-Hex and ALA-Hex at concentrations ranging from 0.03 mM to 1.00 mM. Higher prodrug concentrations (2.00 mM and 3.30 mM) were also tested initially (results not shown), but due to the cytotoxicity in the case of PSI-ALA-Hex and ALA-Hex, it was decided that the concentrations up to 1.00 mM would be used for further in vitro experiments. Figure S2 ). PC3 cells showed the highest PpIX production per cell, followed by the MCF7. Again, in both of these cell lines, the amount of PpIX synthesized from phosphatase-sensitive prodrugs was comparable to ALA-Hex. T24 and A549 produce less PpIX compared to the other cancer cells.
Dark-and photo-toxicity
No dark toxicity was observed for the tested concentrations of phosphatase-sensitive prodrug of 5-ALA, P-ALA-Hex in all cell lines incubated with the product in the dark for 24 h ( Figure S3 ).
In the case PSI-ALA-Hex, its dark-toxicity depends on the cell type. While no dark-toxicity can be seen in PC3 and A549 cells, PSI-ALA-Hex shows some cytotoxicity at 1.00 mM concentration 
Subcellular localization of PpIX
Since the highest amounts of PpIX were produced in the MCF7 human breast adenocarcinoma and PC3 prostate cancer cells upon exposure to phosphatase-sensitive prodrugs and ALA-Hex, these two cell lines were chosen as model cells for the subcellular localization of PpIX. 
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Discussion
Major efforts have been undertaken to find the optimal strategy for the systemic delivery of 5-ALA. Best clinical outcome is reached when optimal equilibrium between molecule's ability to pass biological barriers, cell entry, PpIX induction and low toxicity is achieved. Under physiological pH found in the systemic circulation, 5-ALA is a zwitterion which greatly impairs its ability to pass biological barriers. Despite the fact that many different strategies have been employed in order to tackle this problem, up to date, the best option remains to be the esterification of 5-ALA carboxylic function. A plethora of 5-ALA esters has been reported with the improved lipophilicity and cell uptake. 27, 28 However, most of these molecules still remain considerably toxic and therefore not suitable for systemic administration 13, 20 . Furthermore, the unprotected 5-amino group makes the molecule chemically unstable at physiological pH found in bloodstream leading to its degradation and irreversible formation of cyclic dimers that are not able to enter the heme cycle. 29, 30 Although different strategies have been employed in order to protect the 5-amino group of 5-ALA while keeping some pharmacological activity, they did not really provide any promising candidates for further development. 31, 32 Our approach to protect the amino group in 5-ALA from degradation by integration of phosphatase-sensitive moieties aims at providing the stability needed for the systemic administration of 5-ALA whilst keeping the toxicity profile low. As it was previously reported, both protease-sensitive prodrugs are better tolerated in chick embryos than ALA-Hex. Moreover, the acute in vivo toxicity studies showed a 5-fold increase in the tolerated dose of P-ALA-Hex compared to ALA-Hex. 21 In this study we compared PSI-ALA-Hex and P-ALA-Hex to ALA-Hex by assessing the efficacy of the novel prodrugs to induce the formation of PpIX in five different cancer cell lines.
We also evaluated the cytotoxic effects of the prodrugs in the dark and upon the exposure to different light doses. Furthermore, we investigated the subcellular distribution of PpIX over time.
The results show that all the cells used in this study are capable to produce PpIX after exposure to phosphatase-sensitive prodrugs. Altogether, the optimal concentration of PSI-ALA-Hex to induce the maximum PpIX production in cells can be compared to ALA-Hex and is between 0.03 and 0.33 mM. On the other hand, a higher dose than 1.00 mM of P-ALA-Hex is needed to induce the optimal cell response. This is most likely a consequence of different activation rates between the two phosphatase-sensitive prodrug classes needed for the conversion to 5-ALA. 21 The phenyl-phospho group of P-ALA-Hex is not an optimal substrate for alkaline phosphatases and has a very narrow concentration range for optimal activity hence the higher concentrations needed for activity. 33 Furthermore, this study revealed that T24 and A549 cells produce significantly less PpIX in comparison to PC3 and MCF7 when exposed to 5-ALA prodrugs. Flow-cytometry PpIX normalized fluorescence intensities values at 4 h upon the incubation with 0.33 mM PSI-ALA-Hex vary from 300 for T24 human bladder cancer and 160 for A549 lung adenocarcinoma to 3150 in the case of PC3 prostate cancer and 1200 for MCF7 breast adenocarcinoma cells ( Figure S2 ).
This provides good foundations for the diagnosis or treatment of prostate and breast cancer.
Consequently, these findings explain lower efficacy of PDT in T24 and A549. It has been established that the efficacy of PDT is closely related to the amount of PpIX produced in cells, rather than the irradiation dose used. 34, 35 Moreover, Moan et al. showed that PpIX generation in cells is cell density and cell volume dependent being higher in G2 and M phase in comparison to G1. 36 Another explanation for the discrepancies in phototoxicity results between different cell lines may come from the fact that the photosensitivity of cells is larger in high-density cultures 36 . The low induction of PpIX production upon the incubation with phosphatase-sensitive prodrugs and not with the ALA-Hex in T24 cells might be due to the low expression levels of alkaline phosphatase previously reported in these cells. 37, 38 Also, T24 were initially plated in lower density possibly making them less photosensitive than the PC3 and MCF7 cells.
ALA-prodrug induced PpIX synthesis, accumulation and its subcellular localization are governed by several factors that differ between cell types. The first factor that has to be taken into consideration is the prodrug's uptake mechanism and the rate of uptake, followed by prodrug's metabolism which implicates the expression of different enzymes. Next, mitochondrial metabolic activity and the expression of porphyrin transporters like ABCB6 and ABCG2 has to be taken into consideration. [39] [40] [41] In spite of the fact that all cell lines used in our experiments are capable of PpIX production upon the incubation of different precursors namely, PSI-ALA-Hex, P-ALA-Hex and ALA-Hex, important differences can be seen in the quantity of PpIX produced depending on the cell line, type of precursor and its concentration. These results can be explained by the fact that each of the precursors used has a different metabolic rate to yield the 5-ALA which enters into the heme cycle. While ALA-Hex, the esterase cleavage directly leads to 5-ALA formation, PSI-ALAHex and P-ALA-Hex are activated in several steps (Figure 2) . Although abundantly present in tissues, the regulation of alkaline phosphatase expression changes due to different factors according to cell type. 24, 42, 43 It has to be noted that PSI-ALA-Hex upon activation gives rise to the production of formaldehyde. Although participating in fundamental biological pathways in cells, the excessive amounts of formaldehyde have toxic effects by inhibiting cell proliferation and leading to apoptosis through the upregulation of tumor suppressor genes p53 and p21 responsible for the cell cycle regulation. 44 Formaldehyde disposal from cells include its reduction to methanol via the cytosolic alcohol dehydrogenase (ADH) or by the oxidation to formate catalyzed by ADH3 in the cytosol or by aldehyde dehydrogenase (ALDH) in the mitochondria. [45] [46] [47] It has already been reported that formaldehyde forming prodrugs can have enhanced cytotoxic effects that are cell type dependent, prodrug concentration and the formaldehyde concentration dependent. 48 The latter may apply on the results obtained by monitoring the PpIX production in different cancer cell types ( Figure 3 , 4, S1 and S2).
Studies of subcellular localization of PpIX are important because ROS that are formed during the PDT have a very short half-life hence the mechanisms of action and effectiveness of PDT will depend on where in the cell the PpIX is located. 49 These findings may improve the current use of PDT and PD in clinics enabling personalized and more targeted cancer therapy and diagnoses. Our results are generally in agreement with previously reported studies of PpIX subcellular accumulation which demonstrate its dependence on the cell type used for the experiment. 40, 50, 51 Fluorescence images and the calculation of PCC indicate that PpIX accumulation is dependent on cell type but does not change for ALA-Hex and new 5-ALA derivatives, PSI-ALA-Hex and P-ALA-Hex. Different correlation values between PpIX fluorescence and mitochondria were
